Effect of genetic polymorphisms involved in folate metabolism on the concentration of serum folate and plasma total homocysteine (p-tHcy) in healthy subjects after short-term folic acid supplementation: a randomized, double blind, crossover study by Cabo, Rona et al.
RESEARCH PAPER
Effect of genetic polymorphisms involved in folate metabolism
on the concentration of serum folate and plasma total
homocysteine (p-tHcy) in healthy subjects after short-term folic
acid supplementation: a randomized, double blind, crossover
study
Rona Cabo • Sigrunn Hernes • Audun Slettan •
Margaretha Haugen • Shu Ye • Rune Blomhoff •
M. Azam Mansoor
Received: 12 November 2014 / Accepted: 23 February 2015 / Published online: 11 March 2015
 Springer-Verlag Berlin Heidelberg 2015
Abstract Data on the effect of combined genetic poly-
morphisms, involved in folate metabolism, on the con-
centration of serum folate after folic acid supplementation
are scarce. Therefore, we investigated the impact of seven
gene polymorphisms on the concentration of serum folate
and p-tHcy in healthy subjects after short-term folic acid
supplementation. In a randomized, double blind, crossover
study, apparently healthy subjects were given either 0.8 mg
folic acid per day (n = 46) or placebo (n = 45) for
14 days. The washout period was 14 days. Fasting blood
samples were collected on day 1, 15, 30 and 45. Data on
subjects on folic acid supplementation (n = 91) and on
placebo (n = 45) were used for the statistical analysis. The
concentration of serum folate increased higher in subjects
with higher age (53.5 ± 7.0 years) than in subjects with
lower age (24.3 ± 3.2 years) after folic acid supplemen-
tation (p = 0.006). The baseline concentration of serum
folate in subjects with polymorphism combination, reduced
folate carrier protein, RFC1-80 GA and methylenete-
trahydrofolate reductase, MTHFR677 CT?TT, was lower
than RFC1-80 AA and MTHFR677 CT?TT (p = 0.002).
After folic acid supplementation, a higher increase in the
concentration of serum folate was detected in subjects with
polymorphism combination RFC1-80 GA and MTHFR677
CC than RFC1-80 GG and MTHFR CT?TT combination
(p\ 0.0001). The baseline concentration of plasma total
homocysteine (p-tHcy) was altered by combined poly-
morphisms in genes associated with folate metabolism.
After folic acid supplementation, in subjects with com-
bined polymorphisms in methylenetetrahydrofolate dehy-
drogenase, MTHFD1-1958 and MTHFR-677 genes, the
concentration of p-tHcy was changed (p = 0.002). The
combination of RFC1-80 and MTHFR-677 polymorphisms
had a profound affect on the concentration of serum folate
in healthy subjects before and after folic acid
supplementation.
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Introduction
Folate deficiency increases the risk of cardiovascular dis-
eases (CVD), certain types of cancer and possibly decline
in cognitive abilities (Daly et al. 1995; Shane 2010).
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Maternal folate deficiency and genetic polymorphisms in
folate metabolism have also been linked to neural tube
defects (NTDs) in new born babies (Etheredge et al. 2012).
An attempt to reduce the prevalence of NTDs in the USA,
the fortification of wheat flour with folic acid was started in
1998 (US FDA 1996). Furthermore, folic acid supple-
mentations have been used to reduce the concentration of
plasma total homocysteine (p-tHcy) in patients with hy-
perhomocysteinemia, which has been associated with CVD
(Finch and Joseph 2010).
Folic acid is transported in the intestinal cells by a
proton-coupled folate transporter (PCFT) (Zhao et al. 2011;
Yee et al. 2010). Mostly in liver, intracellular folic acid is
first reduced to dihydrofolate and later to tetrahydrofolate
(THF) by the enzyme dihydrofolate reductase (DHFR).
The enzyme serine hydroxymethyltransferase (SHMT)
converts THF into methylenetetrahydrofolate (methylene-
THF), which is reduced to 5-methyl-THF by methyl-
enetetrahydrofolate reductase (MTHFR). Vitamin B12 and
5-methyl-THF participate in remethylation of homocys-
teine into methionine by methionine synthase (MTR) (Daly
et al. 1995; Shane 2010). Dietary folates do not enter di-
rectly into the intestinal cells. The enzyme c-glutamylhy-
drolase (GH) removes glutamate residues from the
polyglutamates and generates folate monoglutamates,
which are transported in the cells by a reduced folate car-
rier 1 (RFC1). RFC1 mediates bidirectional movement of
folates across the cell membrane; therefore, an efficient
RFC1 may maintain an optimal concentration of intracel-
lular and extracellular folates (Zhao et al. 2011; Yee et al.
2010). Intracellular folate monoglutamates are topped with
glutamate to form polyglutamates by the enzyme
folylpolyglutamate synthase (FPGS). The newly formed
polyglutamates are trapped and stored in the cells (Daly
et al. 1995; Shane 2010).
Intracellular folates are essential for the synthesis of
thymidylate; the reaction is performed by the enzyme
thymidylate synthase (TS). The enzyme, methylene-THF-
dehydrogenase1 (MTHFD1), provides 5, 10-methylene-
THF and 10-formyl-THF, which are involved in the syn-
thesis of DNA. Folate is also involved in the conversion of
serine to glycine, where serine provides one-carbon units
for the folate-dependent one-carbon reactions (Daly et al.
1995; Shane 2010).
Previously, it had been reported that individual poly-
morphisms in MTHFR-1298A[C and MTHFR-1317T[C
did not have any effect on the concentration of p-tHcy;
however, subjects with MTHFR-677 TT had significantly
higher concentrations of p-tHcy (Pereira et al. 2004; Devlin
et al. 2006; Zappacosta et al. 2014; Yang et al. 2008;
Anderson et al. 2013). It was also reported that folic acid
intake (150 lg/day) in subjects with MTHFR677 TT had a
counter effect and reduced the concentration of p-tHcy
(Yang et al. 2008). Moreover, subjects with interaction
between MTHFR-677 TT and RFC1-80 GG had increased
concentration of p-tHcy (Devlin et al. 2006). In women,
with unexplained recurrent miscarriages, 0.5 mg folic acid
supplementation caused a significant reduction in the
concentration of p-tHcy; however, the effect was pro-
nounced in women with the highest baseline concentration
of p-tHcy and MTHFR-677-TT polymorphism (Nelen et al.
1998).
Most studies have reported the effect of individual
polymorphisms on the concentration of p-tHcy and serum
folate, besides the reported data are not consistent. Fur-
thermore, data on the combined effect of gene polymor-
phisms, in folate metabolizing genes, on the concentration
of serum folate and p-tHcy after folic acid supplementation
are scarce (Pereira et al. 2004; Devlin et al. 2006; Zappa-
costa et al. 2014; Yang et al. 2008; Anderson et al. 2013;
Nelen et al. 1998; DeVos et al. 2008). Therefore, in a
crossover study, we assessed the combined effect of
MTHFR-677C[T, MTHFR-1298A[C, RFC1-80G[A,
MTHFD1-1958G[A, MTR-2756A[G, DHFR-19 del and
TS gene polymorphisms on the concentration of serum
folate and p-tHcy after short-term folic acid supplementa-
tion in healthy subjects.
Materials and methods
Study design and study population
A randomized, double blind, crossover study.
Flow chart diagram of study participants is provided
(Fig. 1). Inclusion criteria were healthy male and female
subjects, who were not using any drugs, medications or
vitamin supplementations. Individuals with cardiovascular
disease, cancer and diabetes were not included in this
study. Women who were pregnant were not included in this
study. All subjects were ethnic Norwegian. The par-
ticipants reported that they were not suffering from any
disease. Based on their self-reported health evaluation,
apparently healthy employees and students (n = 103) from
University of Agder, Kristiansand, Norway, agreed to
participate in the study (Fig. 1). One hundred and three
subjects were randomized for supplementation. During the
first supplementation trial, they were given either folic acid
(0.8 mg folic acid/per day) (n = 52) or placebo (n = 51)
for a period of 14 days. Twelve subjects dropped out, and
91 subjects completed the study (Fig. 1). Fasting blood
samples were collected before and after the supplementa-
tion period. Individuals who received folic acid during the
first trial received placebo during the second trial and vice
versa. Washout period between the two trials was 14 days.
All subjects provided fasting blood sample in the morning
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(between 7 am and 9 am) on day 1 (1 day before folic acid
supplementation), day 15, day 30 and day 45. Blood
samples were placed on the ice in the dark. Blood was used
for the isolation of DNA. Serum and plasma were isolated
from the blood samples and were stored at -80 C until all
biochemical and molecular biology analyses were per-
formed. Data from subjects on folic acid supplementation
(n = 91) and subjects on placebo (n = 46) were used for
statistical analyses.
Dietary intake data were collected during the first trial;
the data were available from 96 subjects, who had also
provided the blood samples at the first meeting. Findings
on the dietary intake data were reported previously (Hernes
et al. 2012).
We have reported previously that folic acid supplement,
0.6 mg folic acid, given to healthy individuals increased
the concentration of serum folate significantly after
5 weeks (Mansoor et al. 1999). Based on these observa-
tions, we calculated the sample size based on 80 % power.
The present study was performed according to the
guidelines established in Declaration of Helsinki. The
study protocol was approved by the Regional Committee of
Ethics, Oslo and Data Inspectorate in Norway.
Genotyping
Briefly, reaction volume 20 lL contained 19 Amplitaq
Gold reaction buffer, 500 lM dNTP, 0.5 lM of each pri-
mer (primer sequences are provided in Table 1), 1.25 U
Amplitaq Gold DNA polymerase (Life Technologies Inc.),
3 mM MgCl2 for all polymorphisms except DHFR-19del
and TS, where 1.5 mM MgCl2 was used and 200 ng DNA.
PCR profile was 95 C, 5 min, followed by 35 cycles of
95 C, 30 s, the annealing temperature as specified in
Table 1, 30 s, 72 C, 30 s and final extension incubation at
72 C for 7 min. Some of the polymorphisms were ana-
lyzed by cutting 10 ll PCR products with restriction en-
zyme with the corresponding buffer, at 37 C, overnight.
The products, after PCR and cutting, were analyzed by the
agarose gel electrophoresis (Fredriksen et al. 2007; Cha-
rasson et al. 2009; Frosst et al. 1995; Markan et al. 2007;
Gemmati et al. 2009; Horie et al. 1995; Skibola et al. 2002;
Canalle et al. 2006). In DHFR-19 del, where a 19 nu-
cleotide deletion (D) in intron 1 or wild type, no deletion
(W) was detected. In TS, doublets (2R) or triplets (3R) of
an element of 28 nucleotides in the promoter of the gene
were detected. The resulting product sizes for the gene
polymorphisms are given in Table 1. Details of the PCR
methods have been provided previously (Cabo et al. 2015).
Measurement of folate and vitamin B12 in the serum
samples
The concentrations of serum folate and serum vitamin B12
were measured by a Cobas 6000 in the laboratory of
Medical Biochemistry, Sørlandet Hospital HF, Arendal,
Norway. The coefficient for variation (CV) for the assays
for serum folate and vitamin B12 was\10 %.
Measurement of p-tHcy
The concentration of p-tHcy was measured by an ion-pair
high-performance liquid chromatography (HPLC) method
with a fluorescence detector (Mansoor et al. 1992). The
HPLC method had a CV\ 8 % for the p-tHcy
measurements.
Statistical methods
Data are presented as mean and standard deviation (±SD).
The concentrations of serum folate and p-tHcy had not
normal distribution (Gaussian distribution curve); there-
fore, we used the log-converted values of serum folate and
p-tHcy in statistical analyses (Mansoor et al. 1995). We
Randomised (n=103)
Did not wish to
particiapte in the study
(n=20)
Dropped out
(n=6)
Folic acid (n=52) Placebo (n=51)
Intervention days (n=14)
Placebo (n=46) Folic acid (n=45)
Subjects on folic acid, trial I and
II (n=91)
Invited volunteers
(n=123)
Triasl I
Dropped out
(n=6)
Triasl II
Wash-out period, days (n=14)
Intervention days (n=14)
Placebo treatment
completed (n=45)
Folic acid treatment
completed (n=46)
Fig. 1 Flow chart diagram shows the steps taken for the collection of
blood samples from healthy subjects before and after supplementation
with folic acid and placebo
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tested differences between two groups by Student t test,
and the differences between more than two groups were
estimated by ANOVA. p values \0.05 were considered
significant. We used ANOVA post hoc Bonferroni test for
multiple comparisons to explore the effect of genotype
groups on the concentration of serum folate and p-tHcy. In
this test, p value required for statistical significance was
much lower than 0.05. Age and BMI were compared be-
tween the groups by a nonparametric Mann–Whitney
U test. Kruskal–Wallis test was used for testing comparison
between three parameters. Hardy–Weinberg equilibrium
(HWE) was examined with Chi-square test. We used
Statview 4.5 for the Macintosh for the statistical analyses.
Results
The characteristics of the study participants and the con-
centrations of serum folate and p-tHcy are reported in
Table 2. The concentration of serum folate increased and
the concentration of p-tHcy decreased after folic acid sup-
plementation (p\ 0.0001 and p = 0.0001); an increase in
the concentration of serum folate was 23.0 ± 30.6 nmol/L
(mean ± SD) and a decrease in the concentration of p-tHcy
was 0.7 ± 1.4 lmol/L (mean ± SD) (Table 2). The base-
line concentration of serum folate in the employees was not
significantly higher than in the students (p = 0.2). How-
ever, the concentration of serum folate increased sig-
nificantly higher in the employees than in the students
(p = 0.006). Only one subject had hyperhomocysteinemia;
the p-tHcy concentration was [15 lmol/L. None of the
study subjects had deficiency of serum folate. Allele fre-
quency for genes has been tested for Hardy–Weinberg
equilibrium and is provided in Table 3.
The subjects on folic acid supplementation had higher
concentration of serum folate after washout and placebo
periods than the baseline concentrations 22.04 ± 6.67
versus 18.05 ± 6.45 nmol/L (mean ± SD) (p \ 0.001).
Table 1 PCR methods used in this study
Gene Primers Annealing
temperature
in PCR (C)
Restriction
enzyme
PCR
product (bp)
References
MTHFR-
677C[T
(S) TGAAGGAGAAGGTGTCTGCGGGA 55 Hinf 198, 175, 23 Fredriksen et al. (2007), Charasson
et al. (2009), Frosst et al. (1995),
Markan et al. (2007)
(AS) AGGACGGTGCGGTGAGAGTG
MTHFR-
1298A[C
(S) CTTTGGGGAGCTGAAGGACTACTA 55 MboII 84, 56, 31,
30, 28, 18
Fredriksen et al. (2007), Charasson
et al. (2009), Frosst et al. (1995),
Markan et al. (2007)
(AS) CACTTTGTGACCATTCCGGTTTG
RFC1-
80G[A
(S) AGTGTCACCTTCGTCCCCTC 55 CfoI 162, 125, 68,
37
Fredrikson et al. (2007), Markan
et al. (2007)
(AS) CTCCCGCGTGAAGTTCTT
MTHFD1-
1958G[A
(S) CACTCCAGTGTTTGTCCATG 55 MspI 267, 196, 70,
56, 8
Fredriksen et al. (2007),
Charasson et al. (2009), Markan
et al. (2007)
(AS) GCATCTTGAGAGCCCTGAC
MTR-
2756A[G
(S) TGTTCCCAGCTGTTAGATGAAAAT 55 HaeIII 211, 131, 80 Fredriksen et al. (2007),
Charasson et al. (2009)
(AS) GATCCAAAGCCTTTTACACTCCTC
DHFR-
19del
(F1) CCACGGTCGGGGTACCTGGG 63 113, 92 Gemmati et al. (2009), Horie et al.
(1995), Skibola et al. (2002),
Canalle et al. (2006)
(F2) ACGGTCGGGGTGGCCGAC
(R) AAAAGGGGAATCCAGTCGG
TS (P1) GTGGCTCCTGCGTTTCCCCC 62 Gemmati et al. (2009), Horie et al.
(1995), Skibola et al. (2002),
Canalle et al. (2006)
(P2) CCAAGCTTGGCTCCGAGCCGG
CCACAGGCATGGCGCGG
MTHFR methylene tetrahydrofolate reductase, RFC1 reduced folate carrier protein-1, MTHFD 1 methylenetetrahydrofolate dehydrogenase 1,
MTR methionine synthase, DHFR dihydrofolate reductase, TS thymidylate synthase
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Therefore, the combined data on folic acid supplementation
from trial I and trial II (n = 91) and placebo treatment data
from trial I (n = 45) were used in the statistical analysis.
There was a significant difference in the concentration
of serum folate and p-tHcy in individuals with
MTHFR677CC, CT and TT genotypes after folic acid
supplementation (p = 0.01 and p = 0.0006) (Table 3).
We combined homozygote (wild type), heterozygote
and homozygote (variant type) for MTHFR-677C[T ver-
sus MTHFR-1298A[C, RFC1-80G[A, MTHFD1-
1958G[A, MTR-2756A[G, DHFR-19 del and TS poly-
morphisms into groups. The effect of polymorphism
combinations on the concentrations of serum folate and
p-tHcy was explored by multiple comparisons.
The baseline concentration of serum folate was sig-
nificantly different in RFC1-80 polymorphism combina-
tions alone (p = 0.03) Table 4. The concentration was
highest in RFC1-AA and MTHFR677 CT and TT than
other polymorphism combinations (p = 0.002) (Table 4).
The increase in the concentration of serum folate was
significantly different in different genotype combinations,
MTHFR677 versus MTHFR1298, MTHFD11958,
MTR2756, TS and RFC1-80 (p = 0.02, p = 0.03,
p = 0.03, p = 0.04 and p = 0.0003) (Table 4).
The concentration of serum folate in MTHFR1298AC
and CC and MTHFR677CC combination was significantly
higher than MTHFR1298AC and CC and MTHFR677CT
and TT combination (p = 0.005). MTHFD1-1958GA and
AA and MTHFR677CC also showed a significant differ-
ence in the concentration of serum folate than MTHFD1-
1958GG and MTHFR677CT and TT (p = 0.003). Similar
observations were done for TS-2R2R and TS-2R3R and
MTHFR677CC versus TS-2R2R and TS-2R3R and
MTHFR677CT and TT (p = 0.008). The most significant
differences were observed for RFC1GA and
MTHFR677CC versus RFC1GG and MTHFR677CT and
TT and RFC1GA, MTHFR677CC versus RFC1GA and
MTHFR677CT and TT (p \ 0.0001 and p = 0.0002)
(Table 4).
In Table 5, we could show that the baseline concen-
tration of p-tHcy was significantly different in com-
bined polymorphisms, MTHFR677 versus MTHFR1298,
MTHFD1-1958. MTR2756, DHFR19Del, TS and RFC1-80
(p = 0.002, p = 0.007, p = 0.007, p = 0.006, p = 0.006
and p = 0.01). The combination MTHFR1298AA and
MTHFR677CC polymorphisms had lower p-tHcy concen-
tration than MTHFR1298AA and MTHFR677CT and TT
(p = 0.0003). The MTHFD1-1958GA and AA and
MTHFR677CC had also significantly lower concentration
of p-tHcy than MTHFD1-1958GA and AA and MTHFRCT
and TT (p = 0.004). MTR2756AG and GG and
MTHFR677CC versus MTR2756AG and GG and
MTHFR677CT and TT had difference in the concentration
of p-tHcy (0.004). Similar observations were done for two
different combinations of DHFR19Del and MTHFR677
(p = 0.002 and p = 0.002), one for TS and MTHFR677
(p = 0.008) and one for RFC1-80 and MTHFR677
(p = 0.001) (Table 5).
The concentrations of serum vitamin B12 and p-tHcy
were significantly higher in individuals with MTHFR-
677C[T-TT than in individuals with CC and CT poly-
morphisms (p\ 0.05 and p\ 0.05).
Vitamin B12, vitamin B2 and protein intakes were sig-
nificantly different in individuals with MTHFR-1298A[C
polymorphisms (p\ 0.05, p\ 0.05 and p\ 0.05, respec-
tively). Similarly, vitamin B12 intake was significantly
different in individuals with DHFR-19del polymorphism
(p\ 0.05) (Table 6).
Discussion
The baseline concentrations of serum folate and p-tHcy in
the study subjects are in accordance with the previously
Table 2 Age and BMI of the study subjects and the concentrations of
serum folate and p-tHcy before and after folic acid supplementation
All Employees Students
Folic acid group,
number
91 49 42
Age, years 53.5 ± 7.0 24.3 ± 3.2*1
BMI 24.7 ± 3.3 23.9 ± 3.6
Sex, female/male
ratio
71/24
Serum folate,
nmol/L
17.2 ± 6.3 18.0 ± 4.8 16.3 ± 5.5
Serum folate, post-
intervention
40.1 ± 30.7#1 48.1 ± 38.7*2 30.6 ± 11.1*3
p-tHcy, lmol/L 8.4 ± 3.5 8.6 ± 2.3 8.2 ± 4.5
p-tHcy, post-
intervention
7.8 ± 3.0#2 8.2 ± 2.2*4 7.4 ± 3.8*5
Placebo group,
number
46
Serum folate,
nmol/L
16.5 ± 5.6
Serum folate, post-
intervention
17.5 ± 6.3*6
p-tHcy, lmol/L 8.8 ± 4.3
p-tHcy, post-
intervention
8.6 ± 2.9
Female/male ratio 71/24
Data are presented as mean ± SD. Log-converted values of serum
folate and p-tHcy were used in the analyses
*1 p \ 0.0001, *2 p \ 0.0001, *3 p \ 0.0001, *4 p = 0.009,
*5 p = 0.007, *6 p = 0.01, #1 baseline concentrations versus after
supplementation—p\ 0.0001, #2 baseline concentration versus after
treatment—p = 0.0001
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published findings (Mansoor et al. 2011). The increase,
23.0 ± 30.6 nmol/L (mean ± SD), in the concentration
of serum folate and a decrease, 0.7 ± 1.4 lmol/L
(mean ± SD), in the concentration of p-tHcy after folic
acid supplementation, 0.8 mg/day, for 2 weeks, are similar
to the findings, in healthy subjects, reported previously,
increase in serum folate 18.0 ± 1.5 nmol/L (mean ± SD)
and a decrease in p-tHcy 0.9 ± 0.4 lmol/L (mean ± SD)
(Araki et al. 2006). It has also been demonstrated that folic
acid dose, 0.8 mg/day given to healthy subjects, for
12 weeks, increased the concentration of serum folate from
12.9 ± 3.6 to 53.4 ± 28.3 nmol/L (mean ± SD) and re-
duced the concentration of p-tHcy from 11.5 ± 2.8 to
9.6 ± 2.2 lmol/(mean ± SD) (change about 25 %) (Van
Oort et al. 2003). It has been reported that the higher is the
baseline concentration of p-tHcy, the greater is the
reduction in the concentration of p-tHcy after vitamin B12
or folic acid therapy (Mansoor et al. 1999; Homocysteine
lowering trialists’ collaboration 2005; Green 2011; Man-
soor et al. 2013).
The concentration of serum folate, 5-methyl-THF, in-
creased significantly higher in subjects with higher age
than in subjects with the lower age (Table 2). This obser-
vation may suggest that age may affect folate kinetics
during increased bioavailability of folate. Probably, the
concentration of serum folate increases when the folate-
binding sites on the intracellular proteins are saturated or
the cells are unable to utilize the surplus folate in the
regular biochemical reactions.
The baseline concentration of serum folate was not al-
tered significantly by all polymorphisms in folate genes as
reported previously (Table 3) (Pereira et al. 2004; Devlin
Table 3 Concentrations of serum folate and p-tHcy after folic acid supplementation according to the genotypes
Serum folate over baseline and after supplementation p-tHcy over baseline and after supplementation
Allele frequency Baseline After supplementation p value Baseline After supplementation p value
MTHFR-677C[T
CC (n = 40) C:0.67 18.0 ± 6.2 49.5 ± 40.1* \0.0001 7.3 ± 1.9 7.0 ± 1.4** 0.22
CT (n = 43) T:0.33 16.4 ± 5.8 34.6 ± 20.0 \0.0001 8.7 ± 2.3 7.8 ± 2.0 \0.0001
TT (n = 8) 17.8 ± 9.0 26.0 ± 9.4 0.005 12.6 ± 8.9 11.7 ± 7.6 0.32
MTHFR-1298A[C
AA (n = 46) A:0.69 17.9 ± 6.5 35.5 ± 19.3 \0.0001 8.9 ± 4.5 8.2 ± 3.9 0.01
AC (n = 34) C:0.31 16.7 ± 6.3 43.2 ± 35.7 \0.0001 8.2 ± 2.0 7.5 ± 1.5 0.007
CC (n = 11) 15.7 ± 5.4 50.3 ± 48.8 0.0003 7.3 ± 1.7 7.0 ± 1.6 0.3
RFC1-80G[A
GG (n = 26) G:51 16.6 ± 5.1 30.8 ± 11.4 \0.0001 8.1 ± 1.9 7.4 ± 1.4 0.04
GA (n = 41) A:49 16.3 ± 6.0 41.6 ± 33.3 \0.0001 8.7 ± 4.6 8.0 ± 3.8 0.02
AA (n = 24) 19.4 ± 7.5 47.4 ± 37.6 \0.0001 8.3 ± 2.5 7.8 ± 2.4 0.02
MTHFD1-1958G[A
GG (n = 32) G:0.58 16.9 ± 6.2 37.8 ± 29.5 \0.0001 8.3 ± 1.8 7.5 ± 1.4 0.3
GA (n = 41) A:0.42 16.4 ± 4.6 41.0 ± 35.0 \0.0001 8.6 ± 4.7 8.1 ± 4.0 0.02
AA (n = 18) 19.7 ± 9.0 42.0 ± 21.2 \0.0001 8.3 ± 2.5 7.6 ± 2.2 0.003
MTR-2756A[G
AA (n = 54) A:0.78 17.3 ± 6.5 43.2 ± 35.2 \0.0001 8.3 ± 2.3 7.7 ± 1.9 0.008
AG (n = 34) G:0.22 17.4 ± 6.1 35.4 ± 22.1 \0.0001 8.5 ± 4.9 7.7 ± 4.2 0.005
GG (n = 3) 15.0 ± 4.1 35.1 ± 15.8 0.02 9.7 ± 5.5 9.6 ± 5.0 0.9
DHFR-19del
WW (n = 34) W:0.59 16.3 ± 5.2 42.3 ± 35.6 \0.0001 8.4 ± 2.2 7.7 ± 1.7 0.06
WD (n = 36) D:0.41 17.7 ± 6.9 34.0 ± 22.0 \0.0001 8.6 ± 4.9 8.1 ± 4.4 0.14
DD (n = 21) 18.0 ± 6.8 46.3 ± 33.5 \0.0001 8.1 ± 2.3 7.4 ± 1.7 0.0006
TS
2R2R (n = 22) 2R:0.50 18.3 ± 8.4 37.2 ± 26.4 \0.0001 8.2 ± 2.7 7.5 ± 2.1 0.25
2R3R (n = 46) 3R:0.50 17.4 ± 5.5 40.1 ± 30.9 \0.0001 8.8 ± 4.5 8.1 ± 3.9 0.002
3R3R (n = 23) 15.9 ± 5.3 42.7 ± 34.6 \0.0001 7.9 ± 1.5 7.4 ± 1.6 0.03
Data are presented as mean ± SD
* p = 0.01, and ** p = 0.0006 ANOVA test. The genotype distribution for each polymorphism was tested for possible deviation from HWE
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et al. 2006; Zappacosta et al. 2014; Yang et al. 2008;
Anderson et al. 2013; Nelen et al. 1998; DeVos et al.
2008). After the folic acid supplementation, the concen-
tration of serum folate was changed significantly by
MTHFR-677[T polymorphisms (Table 3). However, the
combination of MTHFR677 and RFC1-80 had a significant
impact on the baseline concentration of serum folate
(Table 4). The highest baseline serum folate concentration,
21.7 ± 8.4 nmol/L (mean ± SD), was detected in subjects
with RFC1-80AA and MTHFR-677 CT?TT combination,
whereas the lowest baseline serum folate concentration,
14.7 ± 4.7 nmol/L, was measured in subjects with RFC1-
80 GA and MTHFR-677CT?TT combination (p = 0.002)
(Table 4). Furthermore, after folic acid supplementation,
the subjects with MTHFR-677 CC and RFC1-80GA
polymorphisms had the greatest increase in the concen-
tration of serum folate, whereas the subjects with combi-
nation of MTHFR677 CT?TT and RFC1-80GG had the
Table 4 Concentration of serum folate associated with combined polymorphisms before and after supplementation with folic acid
Baseline
serum folate
p value for the comparison
between polymorphism
combinations
After 2 weeks
serum folate
p value for the comparison
between polymorphism
combinations
MTHFR-677C[T
MTHFR-1298A[C
AA CC (12) 19.6 ± 7.5 36.3 ± 8.8*1
AC?CC CC (28) 17.3 ± 5.6 55.6 ± 47.2 AC?CC,CC–AC?CC,CT?TT
(p = 0.005)
AA CT?TT (34) 17.2 ± 6.1 35.2 ± 21.9
AC?CC CT?TT (17) 15.5 ± 6.8 29.6 ± 11.1
MTHFD1-1958G[A
GG CC (13) 17.7 ± 6.5 50.1 ± 44.3*2
GA?AA CC (27) 18.1 ± 6.2 49.3 ± 39.0 GA?AA,CC–GG,CT?TT (p = 0.003)
GG CT?TT (20) 16.5 ± 5.8 29.1 ± 10.0
GA?AA CT?TT (31) 16.7 ± 6.7 35.9 ± 22.6
MTR-2756A[G
AA CC (24) 16.6 ± 6.2 54.3 ± 45.9*3
AG?GG CC (16) 20.1 ± 5.9 42.2 ± 29.1
AA CT?TT (30) 17.8 ± 6.9 35.1 ± 22.3
AG?GG CT?TT (21) 15.0 ± 5.0 30.3 ± 11.7
DHFR 19del
WW CC (18) 16.3 ± 5.4 50.8 ± 43.5
WD?DD CC (22) 19.3 ± 6.6 48.4 ± 37.9
WW CT?TT (16) 16.2 ± 5.1 33.4 ± 22.5
WD?DD CT?TT (35) 16.8 ± 6.8 33.2 ± 17.3
TS
3R3R CC (12) 16.4 ± 5.3 47.7 ± 41.0*4
2R2R ? 2R3R CC (28) 18.7 ± 6.6 50.4 ± 40.5 2R2R?2R3R,CC-2R2R-2R3R,
CT?TT (p = 0.008)
3R3R CT?TT (11) 15.3 ± 5.4 37.7 ± 27.6
2R2R ? 2R3R CT?TT (40) 17.0 ± 6.5 31.9 ± 15.7
RFC1-80G[A
GG CC (14) 17.6 ± 6.1#1 34.8 ± 11.3*5
GA CC (15) 19.2 ± 6.9 63.3 ± 44.8 GA, CC-GG,CT?TT (p\ 0.0001)
AA CC (11) 16.8 ± 5.6 48.0 ± 52.0
GG CT?TT (12) 15.4 ± 3.5 26.1 ± 10.0 GA,CC-GA,CT?TT (p = 0.0002)
GA CT?TT (26) 14.7 ± 4.7 GA,CT?TT-AA,CT?TT
(p = 0.002)#2
30.4 ± 17.9
AA CT?TT (13) 21.7 ± 8.4 46.9 ± 22.0
Data are presented as mean ± SD. Number of subjects in parentheses. Serum folate concentration is given in nmol/L. ANOVA test
#1 p = 0.03, #2 p = 0.002, *1 p = 0.02, *2 p = 0.03, *3 p = 0.03, *4 p = 0.04, *5 p = 0.0003
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lowest concentration of serum folate 63.3 ± 44.8 versus
26.1 ± 10.0 nmol/L (mean ± SD) (p\0.0001) (Table 4).
These findings suggest that MTHFR-677 CC, probably,
ensures increased formation of reduced folates after folic
acid supplementation and RFC1-80GA affects their
transport across the cell membrane. Therefore, combina-
tions of RFC1-80G[A and MTHFR-677C[T polymor-
phisms may affect the bioavailability of intracellular and
extracellular folate and as a result may disturb the folate
homeostasis after folic acid supplementation in healthy
Table 5 Concentration of p-tHcy associated with combined genotypes before and after supplementation with folic acid
Baseline
p-tHcy
p value for the comparison
between combined polymorphisms
2 weeks
p-tHcy
p value for the comparison
between combined polymorphisms
MTHFR-677C[T
MTHFR-
1298A[C
AA CC (12) 6.6 ± 2.2*1 6.7 ± 1.4
AC?CC CC (28) 7.6 ± 1.7 AA,CC–AA,CT?TT (p = 0.0003) 7.1 ± 1.4
AA CT?TT (34) 9.6 ± 4.8 8.7 ± 4.3
AC?CC CT?TT (17) 8.6 ± 2.3 7.7 ± 1.8
MTHFD1-
1958G[A
GG CC (13) 7.7 ± 1.6*2 7.5 ± 1.3
GA?AA CC (27) 7.2 ± 2.1 GA?AA,CC–GA?AA, CT?TT
(p = 0.004)
6.8 ± 1.4 GA?AA,CC-GA?AA,CT?TT
(p = 0.002)
GG CT?TT (20) 8.8 ± 1.8 7.5 ± 1.4
GA?AA CT?TT (31) 9.6 ± 5.1 8.9 ± 4.5
MTR-2756A[G
AA CC (24) 7.6 ± 2.2*3 7.3 ± 1.6
AG?GG CC (16) 6.9 ± 1.2 AG?GG,CC–AG?GG,CT?TT
(p = 0.004)
6.5 ± 0.8
AA CT?TT (30) 8.8 ± 2.2 8.0 ± 2.1
AG?GG CT?TT (21) 10.0 ± 6.2 8.9 ± 5.3
DHFR 19del
WW CC (18) 7.8 ± 1.8*4 7.1 ± 1.2
WD?DD CC (22) 7.0 ± 2.0 WD?DD,CC–WW,CT?TT
(p = 0.002)
6.9 ± 1.6
WW CT?TT (16) 9.2 ± 2.4 8.3 ± 2.0
WD?DD CT?TT (35) 9.3 ± 4.8 WD?DD,CC–WD?DD,CT?TT
(p = 0.002)
8.4 ± 4.3
TS
3R3R CC (12) 7.6 ± 1.8*5 7.0 ± 1.6
2R2R ? 2R3R CC (28) 7.2 ± 2.0 2R2R ? 2R3R,CC-2R2R ? 2R3R,
CT?TT
7.0 ± 1.3
3R3R CT?TT (11) 8.2 ± 0.8 (p = 0.008) 7.8 ± 1.5
2R2R ? 2R3R CT?TT (40) 9.6 ± 4.7 8.5 ± 4.1
RFC1-80G[A
GG CC (14) 7.9 ± 2.1*6 7.3 ± 1.5
GA CC (15) 6.9 ± 1.9 6.9 ± 1.3
AA CC (11) 7.3 ± 1.6 GA,CC–GA,CT?TT (p = 0.001) 6.7 ± 1.5
GG CT?TT (12) 8.3 ± 1.7 7.5 ± 1.4
GA CT?TT (26) 9.8 ± 5.4 8.6 ± 4.5
AA CT?TT (13) 9.2 ± 2.8 8.6 ± 2.8
Data are presented as mean ± SD. Number of subjects in the parentheses. The concentration of p-tHcy is given lmol/L. ANOVA test
*1 p = 0.002, *2 p = 0.007, *3 p = 0.007, *4 p = 0.006, *5 p = 0.006, *6 p = 0.01
7 Page 8 of 12 Genes Nutr (2015) 10:7
123
T
a
b
le
6
C
o
n
ce
n
tr
at
io
n
s
o
f
se
ru
m
fo
la
te
,
se
ru
m
v
it
am
in
B
1
2
,
in
ta
k
e
o
f
B
-v
it
am
in
s
an
d
in
ta
k
e
o
f
p
ro
te
in
ac
co
rd
in
g
to
th
e
g
en
o
ty
p
es
S
er
u
m
fo
la
te
(n
m
o
l/
L
)
F
o
la
te
in
ta
k
e
(l
g
/d
ay
)
S
er
u
m
v
it
am
in
B
1
2
(p
m
o
l/
L
)
V
it
am
in
B
1
2
in
ta
k
e
(l
g
/d
ay
)
V
it
am
in
B
2
in
ta
k
e
(l
g
/d
ay
)
V
it
am
in
B
6
in
ta
k
e
(m
g
/d
ay
)
p
-t
H
cy
(l
m
o
l/
L
)
P
ro
te
in
in
ta
k
e
(g
/d
ay
)
A
ll
su
b
je
ct
s
1
7
.3
±
6
.0
(1
6
.5
)
2
8
6
±
9
7
(2
8
2
)
3
1
6
±
1
3
4
(2
8
6
)
6
.8
±
3
.5
(6
.2
)
2
.0
±
0
.9
(1
.7
)
1
.7
±
0
.5
(1
.7
)
8
.2
±
3
.2
(7
.7
)
9
6
.1
±
2
6
.8
(9
0
.5
)
M
T
H
F
R
-6
7
7
C
[
T
C
C
(n
=
4
1
)
1
8
.3
±
5
.9
(1
7
.2
)
2
8
9
±
1
0
6
(2
8
8
)
2
7
5
±
7
9
(2
6
1
)*
7
.2
±
4
.3
(5
.9
)
2
.0
±
0
.8
(1
.8
)
1
.7
±
0
.5
(1
.7
)
7
.2
±
1
.7
(7
.1
)*
9
5
.6
±
2
3
.0
(9
1
.8
)
C
T
(n
=
4
6
)
1
6
.3
±
6
.0
(1
5
.3
)
2
8
2
±
9
5
(2
7
3
)
3
2
4
±
1
2
7
(3
1
1
)
6
.5
±
2
.7
(6
.0
)
2
.0
±
0
.9
(1
.7
)
1
.7
±
0
.6
(1
.7
)
8
.5
±
2
.1
(8
.3
)
9
7
.4
±
3
1
.0
(8
9
.6
)
T
T
(n
=
9
)
1
7
.6
±
6
.9
(1
4
.8
)
2
9
2
±
7
0
(2
9
1
)
4
5
9
±
2
4
4
(3
3
6
)
7
.3
±
3
.1
(6
.6
)
1
.8
±
0
.7
(1
.6
)
1
.7
±
0
.3
(1
.5
)
1
1
.5
±
8
.7
(8
.5
)
9
0
.9
±
1
8
.3
(8
7
.0
)
M
T
H
F
R
-1
2
9
8
A[
C
A
A
(n
=
4
7
)
1
7
.9
±
6
.4
(1
6
.6
)
2
7
4
±
8
9
(2
6
7
)
3
2
9
±
1
4
8
(3
1
8
)
6
.5
±
2
.8
(6
.0
)*
1
.8
±
0
.9
(1
.7
)*
1
.6
±
0
.5
(1
.6
)
8
.3
±
4
.1
(7
.5
)
9
1
.5
±
2
4
.5
(8
7
)*
A
C
(n
=
3
8
)
1
6
.7
±
6
.1
(1
6
.1
)
3
0
5
±
1
0
5
(2
9
2
)
3
0
5
±
1
2
4
(2
7
5
)
7
.6
±
4
.3
(7
.1
)
2
.2
±
0
.9
(2
.1
)
1
.9
±
0
.6
(1
.8
)
8
.3
±
2
.1
(8
.1
)
1
0
6
.0
±
2
9
.6
(1
0
2
)
C
C
(n
=
1
1
)
1
6
.5
±
4
.8
(1
6
.3
)
2
6
9
±
1
0
0
(2
7
6
)
3
0
1
±
1
0
6
(2
7
3
)
5
.4
±
1
.5
(5
.5
)
1
.6
±
0
.3
(1
.6
)
1
.6
±
0
.4
(1
.5
)
7
.1
±
1
.6
(6
.8
)
8
1
.5
±
1
2
.2
(8
2
.1
)
R
F
C
1
-8
0
G
[
A
G
G
(n
=
2
7
)
1
6
.3
±
5
.1
(1
5
.2
)
2
9
1
±
1
1
4
(2
7
2
)
2
7
5
±
7
9
(2
5
7
)
7
.1
±
5
.3
(5
.8
)
1
.9
±
0
.9
(1
.7
)
1
.7
±
0
.6
(1
.6
)
7
.8
±
1
.5
(8
.1
)
9
3
.2
±
2
9
.0
(8
5
.5
)
G
A
(n
=
4
4
)
1
7
.0
±
6
.0
(1
6
.8
)
2
7
8
±
9
3
(2
8
4
)
3
4
5
±
1
4
8
(2
9
9
)
6
.5
±
2
.3
(6
.1
)
1
.9
±
0
.7
(1
.7
)
1
.7
±
0
.5
(1
.6
)
8
.5
±
4
.3
(7
.6
)
9
5
.9
±
2
2
.8
(9
0
.4
)
A
A
(n
=
2
5
)
1
8
.8
±
7
.1
(1
6
.6
)
2
9
6
±
8
9
(2
8
5
)
3
1
0
±
1
4
7
(2
8
2
)
7
.2
±
2
.9
(6
.4
)
2
.1
±
1
.1
(1
.7
)
1
.8
±
0
.5
(1
.8
)
7
.9
±
2
.2
(7
.6
)
9
9
.6
±
3
2
.0
(9
3
.8
)
M
T
H
F
D
1
-1
9
5
8
G
[
A
G
G
(n
=
3
4
)
1
6
.9
±
6
.4
(1
6
.7
)
2
9
3
±
9
0
(2
8
8
)
3
2
9
±
1
5
9
(2
9
9
)
6
.4
±
1
.8
(6
.5
)
2
.0
±
0
.7
(1
.9
)
1
.7
±
0
.5
(1
.7
)
8
.2
±
2
.0
(7
.7
)
9
7
.4
±
2
5
.7
(8
8
.8
)
G
A
(n
=
4
3
)
1
6
.6
±
4
.8
(1
5
.7
)
2
9
0
±
1
0
8
(2
8
8
)
3
0
8
±
1
0
7
(2
8
2
)
7
.2
±
4
.4
(6
.2
)
2
.0
±
1
.0
(1
.7
)
1
.7
±
0
.6
(1
.7
)
8
.4
±
4
.3
(7
.5
)
9
7
.4
±
2
9
.6
(9
5
.5
)
A
A
(n
=
1
9
)
1
9
.5
±
7
.7
(1
8
.3
)
2
6
4
±
8
8
(2
3
7
)
3
1
2
±
1
4
4
(2
7
7
)
7
.0
±
3
.6
(5
.7
)
1
.8
±
0
.7
(1
.7
)
1
.7
±
0
.5
(1
.5
)
7
.6
±
1
.8
(7
.7
)
9
0
.8
±
2
2
.9
(8
2
.8
)
M
T
R
-2
7
5
6
A[
G
A
A
(n
=
5
7
)
1
7
.5
±
6
.3
(1
6
.5
)
2
8
7
±
1
0
1
(2
6
7
)
3
2
2
±
1
4
5
(2
9
4
)
7
.0
±
4
.0
(6
.2
)
2
.0
±
0
.9
(1
.7
)
1
.8
±
0
.6
(1
.7
)
8
.0
±
1
.9
(8
.1
)
9
8
.5
±
2
6
.8
(9
2
.4
)
A
G
(n
=
3
6
)
1
7
.1
±
5
.9
(1
6
.6
)
2
9
2
±
9
2
(2
8
8
)
3
0
4
±
1
1
0
(2
7
8
)
6
.9
±
2
.5
(6
.3
)
2
.0
±
0
.7
(1
.8
)
1
.7
±
0
.5
(1
.7
)
8
.4
±
4
.7
(7
.3
)
9
4
.4
±
2
6
.8
(9
1
.8
)
G
G
(n
=
3
)
1
5
.3
±
3
.6
(1
3
.2
)
2
0
1
±
6
1
(2
0
8
)
3
5
8
±
1
9
8
(2
6
7
)
6
.9
±
2
.5
(6
.3
)
1
.1
±
0
.2
(1
.0
)
1
.1
±
0
.4
(0
.9
)
9
.3
±
4
.1
(7
.2
)
6
8
.8
±
1
1
.5
(7
3
.5
)
D
H
F
R
-1
9
d
el
W
W
(n
=
3
8
)
1
6
.4
±
5
.2
(1
5
.7
)
2
8
6
±
9
2
(2
9
1
)
3
2
2
±
1
4
7
(2
7
8
)
5
.6
±
1
.7
(5
.5
)*
1
.8
±
0
.7
(1
.7
)
1
.7
±
0
.6
(1
.7
)
8
.1
±
1
.9
(8
.2
)
9
2
.4
±
2
5
.4
(8
6
.7
)
W
D
(n
=
3
7
)
1
7
.7
±
6
.4
(1
7
.0
)
2
8
8
±
1
0
4
(2
8
4
)
3
1
1
±
1
3
0
(2
8
5
)
8
.2
±
4
.6
(7
.1
)
2
.1
±
1
.0
(1
.7
)
1
.7
±
0
.5
(1
.7
)
8
.3
±
4
.7
(7
.4
)
9
8
.1
±
2
6
.6
(9
1
.3
)
D
D
(n
=
2
1
)
1
8
.1
±
6
.9
(1
6
.8
)
2
8
1
±
9
9
(2
6
4
)
3
1
4
±
1
1
9
(3
2
9
)
6
.6
±
2
.5
(5
.8
)
1
.9
±
0
.8
(1
.9
)
1
.7
±
0
.5
(1
.7
)
8
.0
±
2
.2
(8
.1
)
9
9
.1
±
2
9
.9
(9
6
.2
)
T
S
2
R
2
R
(n
=
2
4
)
1
8
.1
±
7
.5
(1
7
.2
)
3
0
1
±
8
6
(2
9
7
)
3
4
1
±
1
5
7
(3
2
9
)
8
.1
±
5
.5
(6
.2
)
2
.1
±
0
.9
(1
.7
)
1
.8
±
0
.4
(1
.7
)
7
.8
±
2
.5
(7
.6
)
1
0
2
.0
±
2
6
.2
(9
5
.4
)
2
R
3
R
(n
=
4
9
)
1
7
.5
±
5
.6
(1
6
.7
)
2
8
3
±
9
9
(2
7
3
)
3
1
6
±
1
4
2
(2
7
3
)
6
.2
±
2
.1
(5
.8
)
1
.9
±
0
.7
(1
.7
)
1
.7
±
0
.6
(1
.7
)
8
.6
±
4
.1
(7
.6
)
9
4
.2
±
2
5
.9
(8
8
.8
)
3
R
3
R
(n
=
2
4
)
1
5
.9
±
5
.6
(1
4
.2
)
2
7
7
±
1
0
7
(2
7
1
)
2
9
3
±
8
6
(2
9
0
)
6
.9
±
2
.8
(6
.9
)
2
.0
±
1
.0
(1
.7
)
1
.6
±
0
.5
(1
.5
)
7
.7
±
1
.3
(7
.9
)
9
4
.0
±
2
9
.5
(8
7
.6
)
D
at
a
ar
e
p
re
se
n
te
d
as
m
ea
n
±
S
D
an
d
m
ed
ia
n
in
p
ar
en
th
es
es
*
S
ig
n
ifi
ca
n
t
d
if
fe
re
n
ce
b
et
w
ee
n
th
e
g
ro
u
p
s
(p
\
0
.0
5
)
Genes Nutr (2015) 10:7 Page 9 of 12 7
123
subjects as well as in patients with different diseases
(Table 4) (Dufficy et al. 2006). These observations are
novel and may suggest that polymorphism combinations, in
folate metabolizing genes, may have significant impact on
the concentration of serum folate in populations consuming
high-dose folic acid supplements and folic acid-fortified
foods on daily basis.
As shown in Table 4, MTHFR-677CC and MTHFR-
1298AC?CC genotypes seem to have an opposite effect on
the concentration of serum folate after folic acid supple-
mentation, which is in accordance with a previously pub-
lished report (Yang et al. 2008).
In subjects on folic acid supplementation, trial I, the
concentration of serum folate was still significantly
higher after the washout period and the placebo treat-
ment than the baseline concentration. This observation
suggests that it takes more than 30 days before the
concentration of serum folate reaches to its baseline
concentration after termination of folic acid supplements.
Previously, even a 30-week washout period after a folic
acid supplementation 400 lg/day for 12 weeks seemed
not to be adequate (Anderson et al. 2013). Thus, these
findings suggest that 5-methyl-THF formed after folic
acid supplementation accumulates and remains in the
serum for longer periods.
The lowest concentration of p-tHcy was detected in
subjects with combined polymorphism in MTHFR-677 CC
and MTHFR-1298 AA, 6.6 ± 2.2 lmol/L (mean ? SD),
whereas the subjects with MTR-2756 AG?GG and
MTHFR677 CT?TT, and RFC1 GA and MTHFR677
CT?TT polymorphisms had the highest concentrations of
p-tHcy among six polymorphism combinations tested in
this study (10.0 ± 6.2 and 9.8 ± 5.4 lmol/L (mean ± SD)
(Table 5). It has been reported previously that subjects,
with MTHFR-677 TT and RFC180 GG combination, have
high baseline concentrations of serum homocysteine
(Devlin et al. 2006). The possible explanation is the dif-
ference in the concentration of serum folate in subjects
with these three polymorphism combinations, serum folate
19.6 ± 7.5, 15.0 ± 5.0 and 14.7 ± 4.7 nmol/L, respec-
tively (mean ± SD) (Table 4). The concentrations of
p-tHcy and serum folate are within the normal range in
these subjects. Our observations that subjects with
MTHFR-677 CC, CT and TT have significantly different
concentrations of p-tHcy are in accordance with an earlier
study (Table 3) (Pereira et al. 2004; Devlin et al. 2006;
Zappacosta et al. 2014; Yang et al. 2008; Anderson et al.
2013; Nelen et al. 1998).
Our findings as reported in Table 5 suggest that poly-
morphisms in genes associated with folate metabolism af-
fect mainly the baseline concentrations of p-tHcy in
healthy subjects. It will be interesting to find out whether
these polymorphisms have a significant impact on the
concentrations of p-tHcy in patients with hyperhomocys-
teinemia after folic acid supplementation.
We observed a stepwise, gradient, increase in the con-
centration of serum vitamin B12 in subjects with MTHFR-
677 polymorphisms, CC = 275 ± 79 pmol/L, CT =
324 ± 127 pmol/L and TT = 459 ± 244 pmol/L
(mean ± SD) (Table 6). The question is to measure the
concentration of serum methylmalonic acid (MMA) and
mean corpuscle volume (MCV) in TT individuals to find
out whether they have lower intracellular concentrations of
vitamin B12 than the individuals with CC and CT geno-
types. Or this is a random finding? Similarly, intake of
vitamin B12, vitamin B2 and proteins may be characterized
according to genetic polymorphisms (Table 6); however,
we do not have any evidence, which suggests that genetic
polymorphisms may affect the intake of micronutrients by
healthy subjects. More studies may be required to address
these issues.
Possible clinical consequences
Probably, small serum folate concentration \10 nmol/L
causes an increase in the concentration of p-tHcy, and
serum folate concentration C12 nmol/L keeps p-tHcy
concentration \15 lmol/L. Furthermore, serum folate
concentration[16 nmol/L in mothers seems to reduce the
risk of NTD in babies (Daly et al. 1995; Shane 2010;
Etheredge et al. 2012; Us 1996; Green 2011). Thus, un-
physiological serum folate concentration, C50 nmol/L,
may not cause further reduction in the concentration of
p-tHcy, neither impact one-carbon metabolism nor affect
blood cell homeostasis (Table 5). Previously, elderly, who
consumed 600 lg folic acid added in the bread, had serum
folate concentration from 19.0 to 49.5 nmol/L and folic
acid concentration from 1.03 to 7.22 nmol/L (Kelly et al.
1997). It was also reported that the individuals who had
serum folate concentrations\50 nmol/L had only 2.3 %
folic acid, but the individuals who had serum folate con-
centrations [50 nmol/L had 15.7 % folic acid in the
serum (Pfeiffer et al. 2004). These observations suggest
that after folic acid supplementation, folic acid and
5-methyl-THF accumulate in the blood in subjects on
high-dose folic acid supplementation. Therefore, the
question is whether individuals using high-dose folic acid
supplements for long periods may be exposed to transient
folic acid stress? Previously, it was reported that folate and
zinc had a mutual inhibitory effect at the site of intestinal
transport or absorption (Ghishan et al. 1986). It was also
reported that women with the highest quartile folate and
the lowest quartile zinc were vulnerable to fetomaternal
complications (Mukherjee et al. 1984). Recently, it was
demonstrated that high-dose folic acid supplements
were associated with adverse effects on fetal mouse
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development (Mikael et al. 2013). It was also shown that
folic acid supplements (400 lg) given every other day to
individuals who were consuming diet providing about
3.5 mg zinc were associated with increased loss of zinc
via faces (Milne et al. 1984). In patients with cervical
dysplasia, the concentration of zinc in blood cells was not
reduced significantly, when they consumed 10 mg folic
acid daily for 2–4 months (Butterworth et al. 1988). A
recent report suggested that high-dose folic acid might
promote the progression of mammary tumors in rat
(Manshadi et al. 2014). Furthermore, a clinical trial based
on vitamins folic acid, vitamin B12 and vitamin B6 sup-
plements was terminated before time due to the concern of
possible adverse effects of the B-vitamin supplements in
patients with heart disease, even though the concentra-
tion of p-tHcy was reduced about 30 % (Ebbing et al.
2008). Nevertheless, no link between folic acid supple-
mentation and CVD and cancer was established (Clarke
et al. 2010).
Limitations and strengths
The washout period in our investigation was short. How-
ever, it does not seem to affect the outcome of folic acid
supplementation. The number of study subjects might be
higher to explore the effect of polymorphisms and age on
the concentration of serum folate. However, when the data
collected from, subjects on folic acid supplementation
participating in, trial I and trial II were combined (n = 91),
the effect of polymorphism combinations was significant
on the pre- and post-intervention concentration of serum
folate and p-tHcy. Therefore, in our view, our findings
might be useful for designing new studies to assess the
effects of increased folic acid consumption on trace ele-
ment homeostasis and on the concentration of biomarkers
for CVD and cancer.
Conclusion
Combination of MTHFR-677 and RFC-1 polymorphisms
has a profound impact on the concentration of serum folate
in healthy subjects after short-term folic acid supplemen-
tation. Furthermore, polymorphisms in genes coding for
folate metabolism affect the baseline concentration of
p-tHcy in healthy subjects.
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